Looking back at “Models of Lung Disease” 2018

German-Australian iCAIR project launched by Fraunhofer

Integrated into the seminar agenda, this year’s “Models of Lung Disease” included a very special highlight: the official launch of the German-Australian project iCAIR. The aim of this project is to develop new anti-infective drugs.

Margalit Levin of the Australian embassy in Berlin said, “The iCAIR project joins a growing list of outstanding science, innovation and research projects between Germany and Australia, with the potential for significant global impact. This collaboration between Fraunhofer ITEM, Hannover Medical School and Griffith University’s Institute for Glycomics is proving once again that distance is no longer a barrier when pursuing research excellence – and will now work together to tackle the global imperative of developing new anti-infective therapies.”

Click here for more information about the collaborative project iCAIR.

© Fraunhofer ITEM

“Medicine needs new treatments to combat infection, and this translates into an urgent need to develop new drugs. High development costs, the likely brief treatment time, and the potential for bacterial resistance have been putting companies off, since they are wary of losing money,” explains Prof. Armin Braun, Division Director of Preclinical Pharmacology at Fraunhofer ITEM and iCAIR project manager.

Participants’ opinions

© Fraunhofer ITEM

Prizes awarded for three scientific posters

© Fraunhofer ITEM

From left to right: Tatjana Decaesteker, Patricia Ramos Ramirez, Olaf Holz

At the end of day 1 of this seminar, prizes were awarded to the authors of the best three posters. Congratulations!

1st prize: Tatjana Decaesteker from KU Leuven, “Airway hyperreactivity and epithelial damage in a murine model of swimmers’ asthma”.

2nd prize: Patricia Ramos Ramirez from Karolinska Institutet , “A novel HDM-induced asthma model in quinea pig: a role of mast cells in ariway hyperresponsiveness”.

3rd prize: Lucas Küppers/Olaf Holz from Fraunhofer ITEM, “Breath volatile organic compounds of lung transplant recipients with and without chronic lung allograft dysfunction”.